CP-31398 dihydrochloride|cas:1217195-61-3|西域试剂

CP-31398 dihydrochloride,98.29%

产品编号：Bellancom-18343A| CAS NO：1217195-61-3| 分子式：C₂₂H₂₈Cl₂N₄O| 分子量：435.39

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-18343A	￥800.00	杭州北京（现货）
Bellancom-18343A	￥1300.00	杭州北京（现货）
Bellancom-18343A	￥2500.00	杭州北京（现货）
Bellancom-18343A	￥4000.00	杭州北京（现货）
Bellancom-18343A	￥6500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

CP-31398 dihydrochloride

产品介绍

CP-31398 dihydrochloride 在 p53 突变或野生型的癌细胞中，稳定 p53 的活性构象、促进 p53 的活性。

生物活性

CP-31398 dihydrochloride stabilizes the active conformation of p53 and promotes p53 activity in cancer cell lines with mutant or wild-type p53.

体外研究

CP-31398 (36.75 μM, 16 h) induces p21 in p53-mutant cells.
CP-31398 (15 μg/mL, 20 hours) could induce apoptosis and cell cycle arrest in SW480 cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	Saos-2 cells expressing transfected mutant p53.
Concentration:	36.75 μM.
Incubation Time:	16 h.
Result:	Induction of p21 in cells expressing only mutant p53.

Western Blot Analysis

Cell Line:	LN-18 and U87MG cells.
Concentration:	36 μM.
Incubation Time:	16 h.
Result:	Decreased the levels of procaspase 3 and induced cleavage of caspase 7.

体内研究
(In Vivo)

CP-31398 (100 mg/kg, orally) exhibits significant anti-tumor activity in mice models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Small human tumor xenografts in mice.
Dosage:	100 mg/kg.
Administration:	Orally twice daily for 7 days.
Result:	Suppressed A375.S2 tumor growth by -50%.

体内研究

CP-31398 (100 mg/kg, orally) exhibits significant anti-tumor activity in mice models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Small human tumor xenografts in mice.
Dosage:	100 mg/kg.
Administration:	Orally twice daily for 7 days.
Result:	Suppressed A375.S2 tumor growth by -50%.

体内研究

CP-31398 (100 mg/kg, orally) exhibits significant anti-tumor activity in mice models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Small human tumor xenografts in mice.
Dosage:	100 mg/kg.
Administration:	Orally twice daily for 7 days.
Result:	Suppressed A375.S2 tumor growth by -50%.

性状

Solid

溶解性数据

In Vitro:

H₂O : ≥ 100 mg/mL (229.68 mM)

DMSO : 8.33 mg/mL (19.13 mM; ultrasonic and warming and heat to 65°C)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.2968 mL	11.4840 mL	22.9679 mL
5 mM	0.4594 mL	2.2968 mL	4.5936 mL
10 mM	0.2297 mL	1.1484 mL	2.2968 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 0.83 mg/mL (1.91 mM); Suspended solution; Need ultrasonic

此方案可获得 0.83 mg/mL (1.91 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 8.3 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 0.83 mg/mL (1.91 mM); Suspended solution; Need ultrasonic

此方案可获得 0.83 mg/mL (1.91 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 8.3 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明